Comparing a new dupilumab medicine to Dupixent in healthy adults
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult between 18 and 55 years old.
- Your weight is between 110 and 210 lbs, and your body mass index is between 18.5 and 29.9.
- You have not taken dupilumab (Dupixent) before.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use birth control if needed.
- You have not participated in another drug trial or taken an experimental medicine in the past 30 days.
- You can avoid smoking more than 5 cigarettes a day and limit caffeine drinks during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies why eczema (“atopic dermatitis”) varies in severity even when people receive the medicine dupilumab. It may help doctors better predict who responds well and how to monitor treatment.
This trial tests if a new medication, QL2108, works as well as the approved drug Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). You may be able to join if you've had eczema for at least a year and have active symptoms covering a large area of your body.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
This study looks at how well Dupilumab works over time for people with atopic dermatitis (eczema). It includes adults, teens, and children ages 6 and up.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.